19:31 , Feb 22, 2019 |  BC Extra  |  Company News

Indian generics champion Shah passes away

Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, passed away Friday. The trade group's associate secretary-general, Archana Jatkar, confirmed the news to BioCentury. Known in the industry as DG Shah, the executive was CEO of...
01:35 , Feb 15, 2019 |  BC Week In Review  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
21:47 , Feb 14, 2019 |  BC Extra  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
19:52 , Jan 17, 2019 |  BioCentury  |  Regulation

Products on shutdown standby

Products on shutdown standby On Jan. 14, FDA said it has reserves to continue drug reviews for five more weeks if the government shutdown continues. There are at least six PDUFA dates for new products...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:02 , Nov 2, 2018 |  BC Week In Review  |  Company News

Glenmark opens first U.S. manufacturing site

Indian company Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) opened its first U.S. manufacturing site in Monroe, N.C. The company invested $100 million in the site, which has 168 employees and will produce fixed-dose pharmaceutical formulations. Glenmark...
18:21 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Harbour BioMed raises $85M series B on heels of cancer deals

Immuno-oncology company Harbour BioMed (Shanghai, China) raised $85 million in a series B round led by GIC. New investors China Life Private Equity Investment Company and Vertex Ventures also participated as did existing investors AdvanTech...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
19:02 , Aug 30, 2018 |  BioCentury  |  Finance

Building a deeper Harbour

With an $85 million B round in hand, Harbour BioMed plans to advance newly in-licensed clinical programs while simultaneously building its pipeline through its internal platform and co-discovery deals. Singapore sovereign wealth fund GIC led...
22:31 , Aug 27, 2018 |  BC Extra  |  Financial News

Harbour BioMed raises $85M on heels of cancer deals

Immuno-oncology company Harbour BioMed (Shanghai, China) raised $85 million in a series B round led by GIC. New investors China Life Private Equity Investment Company and Vertex Ventures also participated as did existing investors AdvanTech...